Tevogen Bio’s (TVGN) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Tevogen Bio (NASDAQ:TVGN) in a research report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $10.00 target price on the stock.

Tevogen Bio Price Performance

Shares of NASDAQ:TVGN opened at $1.11 on Tuesday. Tevogen Bio has a fifty-two week low of $0.26 and a fifty-two week high of $6.53. The business has a 50-day moving average of $1.36 and a two-hundred day moving average of $1.17.

Insiders Place Their Bets

In other Tevogen Bio news, insider Neal Flomenberg sold 70,384 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $1.09, for a total value of $76,718.56. Following the completion of the sale, the insider now owns 3,898,828 shares of the company’s stock, valued at $4,249,722.52. The trade was a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 173,542 shares of company stock valued at $192,827 over the last quarter. Insiders own 56.60% of the company’s stock.

Hedge Funds Weigh In On Tevogen Bio

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in Tevogen Bio by 31.2% in the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock valued at $465,000 after buying an additional 107,566 shares during the last quarter. HGC Investment Management Inc. acquired a new stake in shares of Tevogen Bio in the third quarter worth $82,000. Northern Trust Corp increased its position in Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after acquiring an additional 13,595 shares during the period. XTX Topco Ltd bought a new position in Tevogen Bio during the fourth quarter worth $55,000. Finally, Barclays PLC boosted its holdings in Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after purchasing an additional 12,847 shares during the period.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.